grafts 52 mm internal diameter) prevents their reliable clinical use. The present studies were undertaken toexamine the effect of hirudin, a thrombin-specific inhibitor, and of the F(ab), fragment of PG-1, a monoclonal antibody (MoAb) directed against guinea pig platelet membrane glycoprotein Ib (GPlb), on AMG patency in an animal model. One-centimeter long segments of expanded polytetrafluoroethylene (ePTFE), 0.88 mm internal diameter, were serially implanted as interposition grafts in the guinea pig femoral arterial systems bilaterally. A control group was treated with 0.5 mL saline intravenously (IV) 30 minutes before limb 1 and limb 2 graft implantation. Three experimental groups were treated with 0.5 mL saline IV before RTIFICIAL microvascular grafts (AMG, grafts 12-mm A internal diameter) undergo early thrombotic failure prohibiting their clinical use in cardiac, vascular, transplant, and reconstructive plastic surgery procedures. Although AMG thrombosis is thought to begin primarily by deposition of platelets,' present clinical antiplatelet agents are only minimally able to prolong AMG patency in vivo.' This may be so because they act primarily on the postadhesive steps of platelet recruitment, namely aggregation and secretion. Because it is the initial attachment of platelets to a biomaterial or native vessel surface that both localizes a thrombus and promotes its growth, attempts to prevent the initial attachment of platelets to vessel walls and biomaterials may have merit.'~~ Implantation of an AMG into a vessel creates two new sites for the initiation and growth of a thrombus. The first potential site for thrombus initiation is the vascular graft biomaterial. Initial platelet attachment to expanded polytetrafluoroethylene (ePTFE) and polyethylene surfaces involves the adhesive platelet membrane glycoproteins IIb/ 0 1993 by The American Society of Hematology.
0006-497I/93/8201-0019$3.00/0 limb 1 graft implantation as an animal control and with either 0.5 mL saline containing 1.25 mg/kg IV PG-1 F(ab' ),, (which inhibits ristocetin-induced platelet agglutination and von Willebrand factor binding), hirudin 1 mg/kg IV, or a combination of both agents before limb 2 graft implantation. GPlb inhibition, thrombin inhibition, and the combination resulted in a significant prolongation of AMG patency (P < .005). Whereas thrombin inhibition with hirudin prolonged AMG patency similar to that observed with GPlb inhibition, the combination of GPlband thrombin inhibition provided the overall longest prolongation of AMG patency. These results indicate that both platelet membrane GPlb and thrombin play a role in AMG thrombosis. 0 1993 by The American Society of Hematology.
IIIa (GPIIb/IIIa) and Ib (GPIb).4-7 In vitro blockade of GPIIb/IIIa by 10E5, a specific monoclonal antibody (MoAb) directed against GPIIb/IIla, completely inhibits platelet deposition to polyethylene and inhibits 98% ofplatelet deposition to ePTFE.4-7 Scanning-electron microscopy of the artificial surface shows almost complete absence of platelet deposition, suggesting that initial platelet layer deposition is mediated by GPIIb/IIIa. Specific blockade of GPIb with the antibody 6D1 significantly inhibits platelet deposition to polyethylene and ePTFE.'7 Platelet deposition is restricted to a monolayer suggesting that GPIb is involved in second-layer platelet deposition to an artificial surface.
Thrombin has also been implicated in vascular-graft thrombogenesis. Thrombin activity is present on implanted vascular grafts.' Additionally, thrombin-inhibition delays the development of thrombus formation in vascular grafts implanted into baboons. ' The second site of thrombus formation after graft implantation is the anastomoses where cut vessel ends are sutured to the graft biomaterial. Preparation of the vessel ends and the passage of suture through the vessel wall results in trauma to the vessel with endothelial cell injury and exposure of vessel subendothelium." Platelet membrane GPs are important for initiating a thrombus at a site of vascular injury. The initial attachment of platelets to vessel subendothelium is mediated by GPIb and von Willebrand factor (vWF)."," A deficiency of the GPIb complex, as seen in Bernard-Soulier syndrome, results in an inability of platelets to attach to a zone of vascular Conversely, the spreading of platelets and bridging of platelets with fibrinogen to form a platelet plug, after initial GPIb-mediated attachment, occurs via GPIIb/IIIa."' Similarly, thrombin is involved in the growth of a thrombus at the site of vascular injury. Vessels sustaining trauma possess thrombin acti~ity.'~ Thrombin activity is present on anastomosed human vessel segments.14 Inhibition of thrombin with heparin reduces the incidence of microvascular thrombosis in traumatized ~esse1s.l~ Despite the aforementioned knowledge of platelet-membrane GPs and thrombin in vascular graft thrombosis, the 7.2. Dulbecco's phosphate-buffered saline (PBS) without calcium and magnesium was purchased from GIBCO Laboratories (Grand Island, NY). All constituents were reagent grade.
The single-donor cryoprecipitate was prepared by centrifugation of human blood at 4000g for 5 minutes. The supernatant plateletpoor plasma was collected and frozen at -20°C for 48 hours. The frozen plasma was thawed at 5°C and centrifuged at 3,600g for 15 minutes. The supernatant was withdrawn and the underlying cryoprecipitate was assayed for ristocetin cofactor activity using lyophilized platelets from Bio-tech (Havertown, PA). Materials. ePTFE (0.88-mm internal diameter) grafts were donated by W.L. Gore and Associates, Inc, Flagstaff, AZ. Surgicutt bleeding time devices were purchased from Baxter Healthcare Corp (McGaw Park, IL). Nylon suture (10-0 Ethilon, BV 75-3 needle) was purchased from Ethicon Inc (Somerville, NJ).
Antibody. The MoAb to GPlb, PG-I, was raised against washed guinea pig platelets. The F(ab'), fragment of PG-I was prepared as previously described163" and selected for its ability to inhibit ristocetin-induced platelet agglutination and to immunoprecipitate GPIb from detergent lysates of guinea pig platelets. The PG-I MoAb was isolated from mouse ascites using an antibodypurification column (BioRad, Richmond, CA).I6 The F(ab'), fragments were prepared by digestion with pepsin as previously described by Becker and Miller." The PG-I MoAb inhibits vWF-dependent agglutination caused by ristocetin, yet does not affect ADP, collagen, or thrombin-induced platelet aggregation.l6."' Animal model. Forty-one outbred male Hartley albino certified virus-free guinea pigs (225 to 300 g) were housed in the University of Pittsburgh School of Medicine animal shelter (Pittsburgh, PA), fed appropriate chow and water ad lib, and cared for by the veterinary staff according to NIH Animal Care Procedures.l' The experimental protocol was approved by the Institutional Animal Care and Use Committee at the University of Pittsburgh.
Experimental procedure. Animals were divided into four groups: control (n = 8), GPIb inhibition with PG-1 (n = 8), hirudin (n = 14), and hirudin + PG-I (n = 8). Each of the animals in the control group underwent bilateral serial graft implantation with intravenous (IV) saline injection before limb 1 and limb 2 graft placement to identify the effect of serial graft implantation on AMG patency. Similarly, each of the animals in the experimental groups underwent bilateral serial graft implantation with saline injection IV before limb I graft placement as the animal control and IV injection of the appropriate experimental agent before limb 2 graft placement.
Each animal was weighed then anesthetized with intramuscular injection of ketamine hydrochloride ( 100 mg/kg) and acepromazine maleate ( I mg/kg). Both hind limbs and the abdomen were shaved. The animal was restrained in the supine position and an incision was made from the lower abdomen to the distal thigh. The femoral artery was exposed by partially dividing the gracilis muscle and by ligating posteriorly directed arterial branches. The diameter of the femoral artery was measured using an optical micrometer (Reichert 426C; VWR Scientific, Bridgeport, NJ). In both the control and experimental groups, 0.5 mL of 0.9% saline was then administered IV in either the superficial circumflex iliac vein or the femoral vein and 30 minutes were allowed to elapse. The femoral artery was then bisected between two microvascular clamps (ST-B-2V, Accurate Surgical Scientific Instruments Corp, Westbury, NY) and a 3-mm segment of the vessel was excised.
A 1-cm long ePTFE graft, 0.88-mm internal diameter, which had been previously soaked in PBS for IO minutes, was then implanted into the right femoral artery (limb 1) as an interposition graft using standard microsurgical anastomotic technique (original magnification X 10). Eight interrupted sutures of 10-0 Ethilon were used to create each proximal and distal anastomosis. Normal saline was used to irrigate any blood from the surgical field. When the anastomoses were completed, the microclamps were removed and 2% xylocaine was imgated over the proximal vessel to avoid vasospasm while a stopwatch was activated. The operative site was continuously observed by the surgeon. Time to occlusion (TTO) was identified by the cessation of distal vessel micropulsations and this observation was confirmed by the strip test of vascular patency.,' The strip test was performed by gently placing two forceps on the distal vessel beyond the anastomosis, first milking blood distally, then releasing the more proximally placed forcep to allow refilling, which is reliably indicative of a patent artery and graft.
After graft occlusion, the location of the obstructing thrombus was determined by the surgeon as follows. The distal vessel was ligated and the distal anastomosis was opened. If bleeding occurred after this opening, the mechanism of occlusion was recorded as "DISTAL VESSEL" occlusion. If incision of greater than 1 mm of the distal graft was required to initiate bleeding, the mechanism of graft failure was recorded as "GRAFT" occlusion. Ifthe entire graft could be incised without evidence of proximal vessel bleeding, the mechanism of graft failure was noted as "PROXIMAL VESSEL" occlusion.
The graft was then excised, including 3 mm ofboth proximal and distal femoral artery, and stored in Kamovsky's fixative at 4°C for subsequent light microscopy and transmission electron microscopy (TEM). The limb 1 incision was closed. Continued perfusion of limb 1 was maintained via superficial femoral artery blood flow.
Attention was then directed to the opposite limb, and the left femoral artery (limb 2) was exposed and its diameter measured as previously described. In the saline control group, 0.5 mL of 0.9% saline was administered IV followed by a 30-minute waiting period. In the experimental groups, 1.25 mg/kg of E -1 , I mg/kg of hirudin, or the combination, in 0.5 mL of normal saline, was administered IV followed by a 30-minute incubation period. A I-cm length of 0.88-mm internal diameter ePTFE was then implanted into the limb 2 femoral artery using identical surgical technique as that described for limb l. TTO and observations concerning the appearance of the proximal vessel, graft, and distal vessel were once again made by the surgeon. The graft and neighboring proximal and distal vessel were excised and stored in Karnovsky's fixative.
Finally, a celiotomy was performed and 4.5 mL of blood was collected into a 5-mL syringe with 0.5 mL of 130 mmol/L sodium For personal use only. on October 30, 2017. by guest www.bloodjournal.org From citrate from the inferior vena cava at the level ofthe renal vessels for aggregation studies. The animals were then killed by 1V injection of 1 mEq of potassium chloride.
All microsurgery and determination of both the time to graft occlusion and site of graft occlusion was performed by one surgeon who was blinded to the treatment administered.
Three BTs were determined per animal. The BT was determined at the beginning of the operation, 30 minutes after injection of saline in limb I, and 30 minutes after injection of either saline, PG-I , hirudin, or the hirudin + PG-1 combination in limb 2. This was performed by one individual for all animals based on the technique of Becker and Miller." After placement of a neonatal blood pressure cuff inflated to 54 cm water pressure around the animal's forelimb for 30 seconds, a calibrated incision was made using a Surgicutt BT device. The time to cessation of bleeding was measured by blotting expressed blood with Whatman #1 filter paper (Whatman Intl Ltd, Maidstone, UK) every 30 seconds. The BT was recorded to within 30 seconds of cessation of bleeding. The ratio of the bleeding time after/before limb 2 treatment was calculated to determine the effect of limb 2 saline or the various experimental agents on the BT.
Determination of thrombin time. To determine the successful administration and function of hirudin, a thrombin time was determined by adding 100 pL of bovine thrombin (7 U/mL, mixed in 0.9% NaCI) to 200 pL of platelet-rich plasma (PRP) from blood withdrawn at the end of the operation. A stopwatch was activated and the mixture was gently rotated until the solution clotted. The time to clotting was rounded to the nearest minute. The thrombin time was performed in triplicate and averaged for each animal. The test was arbitrarily stopped when clotting did not occur by I hour.
To document intact platelet function in all animals and successful inhibition of GPI b in the appropriate experimental groups, ADP-induced platelet aggregation and ristocetin-induced platelet agglutination were assessed, respectively. Blood from the inferior vena cava was spun for 4 seconds at 14,000 rpm in a table-top microcentrifuge. For the saline and PG-1 groups, PRP was withdrawn and the platelet count was adjusted to 300,OOO/pL by addition of0.9% saline. This saline addition never exceeded a 1:4 dilution. A 500-pL sample of the 0.9% NaCI-diluted PRP was spun at 14,000 rpm for 5 minutes to obtain platelet-poor plasma (PPP), which was used as a blank in aggregation studies.
Aggregometry was performed using a Lumi-aggregometer (Model 660; Chrono-Log Corp, Havertown, PA). Aggregation in response to 8 pmol/L ADP (final concentration) and agglutination in response to 1.8 mg/mL ristocetin (final concentration) was recorded.
Ristocetin and ADP aggregation studies in the hirudin and hirudin + PG-1 experimental groups were performed using an albumin density gradient technique. Apyrase, 5 U/mL and a volume of Tyrode's buffer (pH 6.5) equal to that of the PRP, was added to the PRP obtained as above. This mixture was gently placed on a previously prepared albumin density gradient consisting of three 300-pL aliquots of 50%, 25%, and 18% bovine albumin solution, respectively. The PRP with the albumin density gradient was centrifuged at 900g for I5 minutes. The Tyrode's and PPP layer, as well as the underlying albumin solution, was carefully removed leaving an intact platelet-rich layer. These platelets were reconstituted with Tyrodes buffer pH 7.3 to a count of 300,0OO/pL. A 500 pL aliquot of the reconstituted platelets was spun at 14,000 rpm for 5 minutes and used as a blank in aggregation studies.
To assess ristocetin agglutination, 240 pL of washed platelets were placed in a siliconized cuvette. Forty microliters of singledonor human cryoprecipitate (final concentration of 1 U/mL vWF,
Measurement of bleeding time (B7J
Performance of aggregation studies. measured as ristocetin cofactor activity) and ristocetin (0.9 mg/mL) were added to the platelets and the change in optical density noted.
To assess ADP aggregation, 40 pL of cryoprecipitate and ADP (8 pmol/L) was added to 250 pL of washed platelets and the change in optical density recorded.
Statistical analysis. Comparison of the TTO between animals of the control group and the experimental groups was made using the Kruskal-Wallis one-way analysis of variance followed by multiple comparisons using a Bonferroni correction. Comparison of the animal weight, the limb 1 and 2 vessel size, the initial bleeding time, the ratio of the bleeding time after/before limb 2 treatment, the hematocrit, the change in the hematocrit from start to end of the experiment, the initial platelet count, the percentage drop in platelet number, and the thrombin time between the control and experimental groups were made using one-way analysis of variance and Kruskal-Wallis one-way analysis of variance when variances were unequal. Comparison of the intraanimal site ofgraft occlusion were made using McNemar's Test.
The mean f two standard deviations was calculated for the limb I TTO in all animals. Animals with a TTO outside this range were excluded from the study. This resulted in the exclusion of two animals from the hirudin group and one animal from the hirudin + PG-I group.
RESULTS

Comparison between control and experimental groups.
The average TTO of the saline limb 1 grafts for the combined control and experimental groups was 9.0 i . 2.6 minutes (mean f SD, n = 38). Because limbs were paired in this study, the TTO data presented along the x axis in Fig 1 is expressed as a ratio of the limb 2 TTO/limb 1 TTO. By expressing the data as a ratio ofthe experimental graft TTO/ saline control graft TTO (ie, limb 2 TTO/limb I TTO), each animal serves as its own control. The Y axis in Fig 1 repre sents the proportion of grafts remaining patent as the ratio of the limb 2 TTO/limb 1 TTO increases along the x axis.
In the saline control group, 63% of the limb 2 grafts remained patent longer than the limb 1 graft in the same animal. This saline control group showed that serial graft implantation alone resulted in a mean 26% prolongation of limb 2 graft patency that was not statistically significant (P = .18, paired Student's t-test). However, to take this into account, each experimental group in Fig 1 (PG-I, hirudin, hirudin + PG-I) was compared with the saline control group so that the small thromboresistance conferred by serial graft implantation was taken into statistical consideration.
In 50% ofthe animals treated with PG-I , the limb 2 experimental graft remained patent at least two times as long as the animal's limb 1 control graft (Fig I) . In 50% of the animals treated with hirudin, the limb 2 experimental graft remained patent at least three times as long as the animal's limb 1 control graft (Fig I) . Finally, in the combination group (hirudin + PG-I), 50% of the limb 2 experimental grafts remained patent four times as long as the limb 1 control graft (Fig 1) . Graft patency time in each of the experimental groups was significantly longer when compared with the saline control group (P < .005 for each expenmental group). While the prolongation of graft patency was similar for the PG-1 -and hirudin-treated animals (P > .05), the addition of hiruFor personal use only. on October 30, 2017. by guest www.bloodjournal.org From Other hematologic and animal parameters that may have contributed to differences in the TTO between the groups were evaluated during the experiment. The four different groups were similar with respect to the animal weight, the limb 1 and limb 2 vessel size, preoperative bleeding time, the change in hematocrit from start to end of the experiment and the initial platelet count ( Table 1 ). The starting hematocrit was 2% to 3% higher and the percentage drop in platelet number was lower in the hirudin group (P = .02 and P = .003 respectively, Table 1 ).
The eflect of PG-1 on the BT. The initial BT between each of the groups was similar ( Table 1) . Administration of the F(ab'), fragment of the MoAb PG-I at a dose sufficient to prolong AMG patency did not result in a significant prolongation of the BT when comparing the ratio of the bleeding time after/before administration of the limb 2 control or experimental agent. Similar results were observed in the hirudin-treated animal groups (Table I ). The thrombin time was significantly and similarly prolonged in the hirudin and hirudin + PG-1 groups (Table I) 
, confirming
The effect of hirudin on the thrombin time.
that the injected hirudin successfully inhibited thrombin function in these groups.
Site of graft failure. The site of graft occlusion was recorded for the saline control and each of the experimental groups as described in Materials and Methods. Eighty-five percent of all implanted grafts failed at the distal anastomosis, 12% failed because of thrombus accumulation within the graft and none of the grafts failed as a consequence of proximal anastomotic thrombus. Two of the limb 2 hirudin grafts remained patent after a 5-hour observation period. There was no statistically significant difference in the site of occlusion between the limb 1 saline control graft and limb 2 experimental graft for each of the groups (McNemar's test, saline P = 1 .O, PG-1 P = 1 .O, hirudin P = .25, hirudin + All animals in the control and experimental groups uniformly showed an aggregation response to ADP at 8 pmol/L. All ofthe animals in the control and hirudin groups displayed typical agglutination tracings in response to ristocetin (0.9 mg/mL). PRP from the PG-1 group and albumin density gradient washed platelets from the hirudin + PG-1 group did not show a change in optical density when exposed to ristocetin, confirming that the injected PG-1 MoAb performed its intended function of GPIb inhibition.
PG-1 P = 1.0). 
Aggregation studies.
Analysis performed using one-way analysis of variance of Kruskal-Wallis analysis of variance. All values represent mean f SD except ET, change in Abbreviations: TX, treatment; HCT, hematocrit.
For % Decrease Platelet Count, the P value refers to the Sal/Hir group, which is significantly less than all other groups. For Thrombin time, the P HCT, and thrombin time, which represent median i-range.
value refers t o the Sal/Hir and Sal/Hir + PG-1 groups, which are significantly greater than Sal/Sal and Sal/PG-1 groups.
For personal use only. on October 30, 2017. by guest www.bloodjournal.org From For personal use only. on October 30, 2017. by guest www.bloodjournal.org From (Figs 2A and B) . TEM of the distal vessel (after the AMG) uniformly showed a large intraluminal thrombus in all groups (Fig 3A) . This thrombus was platelet-rich (Fig 2B) .
DISCUSSION
Previous investigation has shown that ePTFE AMG remain patent with varying but discouraging S U C C~S S .~~-~~ Differences in AMG size, graft length, graft fibril length, drug therapies, and animal models with coexistent coagulation and platelet differences2' account in part for the variability in results. The underlying mechanism of thrombosis in this setting has not been clarified.
When developing a strategy to forestall AMG thrombosis, it is important to identify differences between large and small diameter ePTFE conduits. Large diameter ePTFE grafts (>4 mm internal diameter) have been used with acceptable patency rates, particularly in lower extremity above the knee arterial reconstr~ction.~~ ePTFE AMG differ from these larger grafts in that their surface to blood ratio is higher. Limited degrees of platelet deposition to the former can occur without graft failure whereas the same degree of platelet deposition within an AMG and at the distal anastomosis may disproportionately and suddenly reduce the graft and vessel lumen diameter leading to graft failure.' Therefore, it is our hypothesis that antithrombotic agents directed toward the inhibition of the initial steps in platelet adhesion may be essential to prevent AMG thrombosis. Because thrombin activity is present on anastomosed vessels and vascular grafts and inhibition of thrombin improves AMG patency in the baboon, its inhibition is thought to be essential as To determine whether GPIb inhibition, hirudin, or hirudin + GPIb inhibition would prolong AMG patency in vivo, we developed a guinea pig AMG implantation model.
We used this guinea pig model for several reasons. First, the guinea pig GPIb platelet membrane receptor functions similarly to the GPIb receptor of human platelets in that it both binds vWF and platelet agglutination occurs in response to ristocetin.16 Second, a well characterized anti-GPIb antibody was available that blocks both of these functions.16," Third, the size of the guinea pig femoral artery compares favorably with vessel sizes used in clinical microsurgery (0.75 mm to 1.0 mm). Finally, bilateral serial graft implantation may be performed, allowing paired studies within the same animal without creating ischemia of either limb.
Results of the present study show an increase in graft patency rates with platelet-membrane GPIb inhibition. The thrombin-specific inhibitor hirudin prolonged graft patency rates to a level similar to that of GPIb inhibition with PG-1 alone. However, the addition of hirudin to PG-1 significantly enhanced graft patency rates, as compared with PG-1 alone, suggesting a dependency on both platelet-membrane GPIb and thrombin in AMG failure.
The animals treated with hirudin alone did not have as significant a drop in the platelet count, as compared with the GPIb inhibition and hirudin + GPIb inhibition groups.
The mild thrombocytopenia observed with the F(ab), fragment of the MoAb to GPIb has been previously reported," and may be caused, in part, by splenic sequestration of antibody-coated platelets. This decrease in platelet number combined with the relative platelet sparing effect of hirudin30 may have resulted in the statistically significant difference in platelet number between the groups from the start to the end of the experiment.
In the experiments reported here GPIb inhibition successfully prolonged graft patency without prolonging the bleeding time. This result confirms previous investigations showing a similar lack of bleeding time prolongation in the presence of this antibody."
There are several theoretical reasons why GPIb inhibition enhanced graft patency. It is possible that GPIb inhibition delayed the development of distal anastomotic thrombus formation, thereby prolonging the TTO. A delay in distal anastomotic thrombus formation could occur first by a reduction in intrathrombus stability. PG-1 is known to inhibit vWF-dependent platelet-platelet association.'6.18 This platelet-platelet cohesiveness may be important for the initiation and/or stability and propagation of distal anastomotic thrombus. A previous investigation with PG-1 showed a reduction in thrombus formation at a site of vascular injury induced by a pulsed-dye laser.3' PC-1 did not delay the time to initial thrombus formation in that setting but reduced the redevelopment ofthrombus at the injury site after the initial thrombus emb~lized.~' A delay in distal anastomotic thrombus formation could also occur by attenuating thrombus adherence to the distal vessel wall. The GPIb receptor mediates platelet adhesion to subendothelium and damaged vascular endothelium under high-shear conditions that may occur during the dynamic flow alterations seen after anastomotic ~r e a t i o n .~' .~~ GPIb inhibition may have prevented second and subsequent vertical layer platelet deposition within the graft. Verifying this hypothesis with scanning electron microscopic (SEM) and TEM evaluation of the grafts was not possible because of fibrin blanketing the graft surface.
The thrombin-specific inhibitor hirudin showed equal prolongation of AMG patency to that of GPIb inhibition. Hirudin does not alter platelet function or other coagulation parameter^,^' presumably excluding it as a mediator of AMG thromboresistance outside of its effect on thrombin inhibition. Thrombin has several different activities. It is a potent activator of platelets, leads to the formation and polymerization of fibrin, and is associated with the activation of Factors V, VIII, and XIII.36,37 Identifying which specific thrombin activity hirudin inhibited which resulted in enhanced graft patency has not been investigated and deserves attention.
At least two other factors may be contributing to AMG thrombosis in this model. The first involves the platelet membrane GPIIb/IIIa that has been shown to be an important platelet adhesive GP to artificial surfaces and to vessel subendothelium. Blockade of GPIIb/IIIa completely inhibited platelet deposition to polyethylene in vitro and restricted 98% of platelet deposition to ePTFE in vitro. ' 
